UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported):
November 12 th , 2017
CANNABICS PHARMACEUTICALS INC.
(Exact name of registrant as specified in its charter)
| Nevada | 333-192759 | 20-3373669 |
| (State of incorporation) | (Commission File Number) | (IRS Employer No.) |
#3 Bethesda Metro Center
Suite 700
Bethesda, Md 20814
(Address of principal executive offices and Zip Code)
877 424-2429
(Registrant's telephone number, including area code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the Registrant under any of the following provisions:
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a -12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d -2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e -4(c))
ITEM 5.02 – DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS; APPOINTMENT OF PRINCIPAL OFFICERS.
On November 12 th , 2017, the shareholders of the Corporation elected Eyal Barad as a Director and Chief Operating Officer (COO) of the Company.
Eyal Barad 52, is a co-founder of Cannabics Inc., founded in 2012, and is a core member of Cannabics Inc.’s management team and brings 20 years of executive managerial experience in successful technology and startup ventures. Mr. Barad received his BA in Economics & International Relations from the Hebrew University in Jerusalem in 1994, and an MBA with Honors from Haifa University in 2007.
Related Party – Barad is a shareholder and Board Member of Cannabics Inc., a Delaware corporation and majority shareholder of the Company.
ITEM 9.01 EXHIBITS
(d) Exhibits
10.01 Shareholder’s Resolution
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
Date: November 12 th , 2017
| Cannabics Pharmaceuticals Inc. | ||
| /s/ Itamar Borochov | ||
| By: | Itamar Borochov, Director, CEO | |
| 2 |
Exhibit 10.1
RESOLUTION OF THE SHAREHOLDERS
OF
CANNABICS PHARMACEUTICALS INC.
The following is a true copy of the resolution duly adopted by the Majority of the Shareholders of the Corporation at a special meeting, notice to this meeting having been waived, held this 12 th day of November, 2017;
WHEREAS there has been presented to and considered by this meeting a Motion to elect a new Board of Directors of the Company;
NOW THEREFORE BE IT RESOLVED that the majority of shareholders having considered this matter, and having opened the floor to all those who voice a preference in the issue and pursuant to NRS 78.320, have overwhelmingly decided and RESOLVED that we have elected to join our current Board:
EYAL BARAD, as Director & COO
The Above qualified Director, has been nominated, and has accepted their position as DIRECTOR and COO of the Company.
Said Motion is hereby passed and the corporate books, records and the Company shall file this Resolution in the corporate records.
DATED: 12 th November, 2017
| /s/ Itamar Borochov | |
|
Itamar Borochov, Director, CEO on behalf of Cannabics, Inc., Majority Shareholders |